Nalaganje...

Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies

The withdrawal of pharmaceutical companies from developing drugs against Alzheimer's highlights the inherent difficulties in tackling this devastating disease. In the meantime, biotech companies and basic research explore new targets and drug combinations.[Image: see text]

Shranjeno v:
Bibliografske podrobnosti
izdano v:EMBO Rep
Glavni avtor: Rinaldi, Andrea
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6123640/
https://ncbi.nlm.nih.gov/pubmed/30150324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.201846714
Oznake: Označite
Brez oznak, prvi označite!